Cellectar Biosciences, Inc. (CLRB) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Lose.
18/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 0 wins, 12 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseCLRB / S&P 9.45% / 15.20% |
LoseCLRB / S&P CLRB unavailable / 15.00% |
LoseCLRB / S&P -80.72% / 50.40% |
| 2026-Q10/3 |
LoseCLRB / S&P -13.90% / -4.33% |
LoseCLRB / S&P CLRB unavailable / 11.30% |
LoseCLRB / S&P -69.67% / 27.70% |
| 2025-Q40/3 |
LoseCLRB / S&P -47.32% / 2.65% |
LoseCLRB / S&P CLRB unavailable / 9.00% |
LoseCLRB / S&P -48.14% / 13.40% |
| 2025-Q30/3 |
LoseCLRB / S&P -21.24% / 8.12% |
LoseCLRB / S&P CLRB unavailable / 4.61% |
LoseCLRB / S&P -51.27% / 13.45% |
| 2025-Q21/3 |
LoseCLRB / S&P -25.94% / 10.94% |
LoseCLRB / S&P CLRB unavailable / 4.83% |
WinCLRB / S&P 140.00% / 10.63% |
| 2025-Q12/3 |
WinCLRB / S&P 6.67% / -4.27% |
LoseCLRB / S&P CLRB unavailable / 4.98% |
WinCLRB / S&P 482.49% / 10.57% |
| 2024-Q41/3 |
LoseCLRB / S&P -85.98% / 2.41% |
LoseCLRB / S&P CLRB unavailable / 5.25% |
WinCLRB / S&P 412.98% / 6.15% |
| 2024-Q31/3 |
LoseCLRB / S&P -14.40% / 5.89% |
LoseCLRB / S&P CLRB unavailable / 5.89% |
WinCLRB / S&P 402.13% / 6.11% |
| 2024-Q21/3 |
LoseCLRB / S&P -37.19% / 4.28% |
LoseCLRB / S&P CLRB unavailable / 5.38% |
WinCLRB / S&P 137.82% / 5.12% |
| 2024-Q11/3 |
WinCLRB / S&P 43.68% / 10.56% |
LoseCLRB / S&P CLRB unavailable / 5.71% |
LoseCLRB / S&P -1.05% / 5.59% |
| 2023-Q40/3 |
LoseCLRB / S&P 4.92% / 11.69% |
LoseCLRB / S&P CLRB unavailable / 6.81% |
LoseCLRB / S&P -10.62% / 7.78% |
| 2023-Q31/3 |
WinCLRB / S&P 35.38% / -3.27% |
LoseCLRB / S&P CLRB unavailable / 7.52% |
LoseCLRB / S&P -15.70% / -5.03% |
| 2023-Q21/3 |
WinCLRB / S&P 36.36% / 8.74% |
LoseCLRB / S&P CLRB unavailable / 9.50% |
LoseCLRB / S&P -15.90% / -8.57% |
| 2023-Q11/3 |
LoseCLRB / S&P -16.37% / 7.50% |
LoseCLRB / S&P CLRB unavailable / 10.77% |
WinCLRB / S&P -6.39% / -15.69% |
| 2022-Q41/3 |
LoseCLRB / S&P -49.11% / 7.56% |
LoseCLRB / S&P CLRB unavailable / 11.88% |
WinCLRB / S&P 26.56% / -17.99% |
| 2022-Q31/3 |
LoseCLRB / S&P -16.00% / -4.88% |
LoseCLRB / S&P CLRB unavailable / 13.47% |
WinCLRB / S&P 31.56% / -1.41% |
| 2022-Q21/3 |
LoseCLRB / S&P -42.03% / -16.10% |
LoseCLRB / S&P CLRB unavailable / 13.71% |
WinCLRB / S&P 61.48% / 11.04% |
| 2022-Q11/3 |
WinCLRB / S&P 4.55% / -4.60% |
LoseCLRB / S&P CLRB unavailable / 15.97% |
LoseCLRB / S&P CLRB unavailable / 42.23% |
| 2021-Q40/3 |
LoseCLRB / S&P -29.03% / 11.03% |
LoseCLRB / S&P CLRB unavailable / 15.00% |
LoseCLRB / S&P CLRB unavailable / 96.40% |
| 2021-Q30/3 |
LoseCLRB / S&P -21.85% / 0.58% |
LoseCLRB / S&P CLRB unavailable / 10.77% |
LoseCLRB / S&P CLRB unavailable / 69.42% |
| 2021-Q20/3 |
LoseCLRB / S&P -26.09% / 8.55% |
LoseCLRB / S&P CLRB unavailable / 6.58% |
LoseCLRB / S&P CLRB unavailable / 51.81% |
| 2021-Q10/3 |
LoseCLRB / S&P -22.60% / 6.17% |
LoseCLRB / S&P CLRB unavailable / -1.06% |
LoseCLRB / S&P CLRB unavailable / 7.39% |
| 2020-Q41/3 |
WinCLRB / S&P 67.74% / 12.15% |
LoseCLRB / S&P CLRB unavailable / -3.72% |
LoseCLRB / S&P CLRB unavailable / -33.42% |
| 2020-Q30/3 |
LoseCLRB / S&P -3.13% / 8.93% |
LoseCLRB / S&P CLRB unavailable / -2.04% |
LoseCLRB / S&P CLRB unavailable / -27.10% |
| 2020-Q20/3 |
LoseCLRB / S&P -3.76% / 20.54% |
LoseCLRB / S&P CLRB unavailable / -0.46% |
LoseCLRB / S&P CLRB unavailable / -27.11% |
| 2020-Q10/3 |
LoseCLRB / S&P -40.89% / -19.60% |
LoseCLRB / S&P CLRB unavailable / 3.47% |
LoseCLRB / S&P CLRB unavailable / -14.75% |
| 2019-Q41/3 |
WinCLRB / S&P 12.50% / 9.07% |
LoseCLRB / S&P CLRB unavailable / 5.36% |
LoseCLRB / S&P CLRB unavailable / 2.99% |
| 2019-Q30/3 |
LoseCLRB / S&P -8.26% / 1.70% |
LoseCLRB / S&P CLRB unavailable / 5.02% |
LoseCLRB / S&P CLRB unavailable / 0.21% |
| 2019-Q20/3 |
LoseCLRB / S&P -7.23% / 4.30% |
LoseCLRB / S&P CLRB unavailable / 6.64% |
LoseCLRB / S&P CLRB unavailable / 8.65% |
| 2019-Q11/3 |
WinCLRB / S&P 51.61% / 13.65% |
LoseCLRB / S&P CLRB unavailable / 8.12% |
LoseCLRB / S&P CLRB unavailable / 14.29% |
| 2018-Q40/3 |
LoseCLRB / S&P -48.33% / -13.52% |
LoseCLRB / S&P CLRB unavailable / 9.05% |
LoseCLRB / S&P CLRB unavailable / 18.23% |
| 2018-Q30/3 |
LoseCLRB / S&P -51.61% / 7.71% |
LoseCLRB / S&P CLRB unavailable / 10.21% |
LoseCLRB / S&P CLRB unavailable / 19.06% |
| 2018-Q20/3 |
LoseCLRB / S&P -45.61% / 3.43% |
LoseCLRB / S&P CLRB unavailable / 9.03% |
LoseCLRB / S&P CLRB unavailable / 14.46% |
| 2018-Q10/3 |
LoseCLRB / S&P -16.79% / -0.76% |
LoseCLRB / S&P CLRB unavailable / 7.68% |
LoseCLRB / S&P CLRB unavailable / 12.46% |
| 2017-Q40/3 |
LoseCLRB / S&P -17.96% / 6.64% |
LoseCLRB / S&P CLRB unavailable / 7.03% |
LoseCLRB / S&P CLRB unavailable / 13.82% |
| 2017-Q30/3 |
LoseCLRB / S&P 2.45% / 4.48% |
LoseCLRB / S&P CLRB unavailable / 5.68% |
LoseCLRB / S&P CLRB unavailable / 17.57% |
| 2017-Q20/3 |
LoseCLRB / S&P -28.19% / 3.09% |
LoseCLRB / S&P CLRB unavailable / 4.83% |
LoseCLRB / S&P CLRB unavailable / 17.74% |
| 2017-Q11/3 |
WinCLRB / S&P 86.07% / 6.07% |
LoseCLRB / S&P CLRB unavailable / 3.67% |
LoseCLRB / S&P CLRB unavailable / 13.32% |
| 2016-Q40/3 |
LoseCLRB / S&P -54.98% / 3.82% |
LoseCLRB / S&P CLRB unavailable / 2.09% |
LoseCLRB / S&P CLRB unavailable / 7.05% |
| 2016-Q30/3 |
LoseCLRB / S&P -21.22% / 3.85% |
LoseCLRB / S&P CLRB unavailable / 0.20% |
LoseCLRB / S&P CLRB unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | CLRB total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -47.84% | 20.78% |
| Annualized return | -47.84% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | CLRB total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.20% | 83.14% |
| Annualized return | -61.94% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | CLRB total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.96% | 319.30% |
| Annualized return | -54.32% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |